Taku Kanda

Taku Kanda

Auto-generated profile, based on publicly available information

Taku Kanda

Tokyo University of Pharmacy and Life Sciences 1 School of Life Sciences Hachioji, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
HIHiroki Inoue
Hiroki Inoue
TKTaku Kanda
Taku Kanda
GHGakuto Hayashi
Gakuto Hayashi
RMRyota Munenaga
Ryota Munenaga
MYMasayuki Yoshida
Masayuki Yoshida
MTMitsuo Tagaya
Mitsuo Tagaya
The microtubule-associated protein MAP1B has been implicated in axonal growth and brain development. We found that MAP1B is highly expressed in the most aggressive and deadliest breast cancer subtype, triple-negative breast cancer (TNBC), but not in other subtypes. Expression of MAP1B was found to be highly correlated with poor prognosis. Depletion of MAP1B in TNBC cells impairs cell migration and invasion concomitant with a defect in tumorigenesis. We found that MAP1B interacts with key components for invadopodia formation, cortactin, and Tks5, the latter of which is a PtdIns(3,4)P2-binding and scaffold protein that localizes to invadopodia. We also found that Tks5 associates with microtubules and supports the association between MAP1B and α-tubulin. In accordance with their interaction, depletion of MAP1B leads to Tks5 destabilization, leading to its degradation via the autophagic pathway. Collectively, these findings suggest that MAP1B is a convergence point of the cytoskeleton to promote malignancy in TNBC and thereby a potential diagnostic and therapeutic target for TNBC.